2:35 PM
Apr 17, 2019
 |  BC Extra  |  Preclinical News

Atomwise unveils Chagas disease compounds from AIMS program

Atomwise has revealed the first hit identifications by two of its AIMS program collaborators, including compounds against an unexploited target for Chagas disease, for which there are few therapies.

On Tuesday, Atomwise Inc. (San Francisco, Calif.) and the Drugs for Neglected Diseases initiative (DNDi) announced the discovery of compounds targeting Trypanosoma cruzi, which causes Chagas disease.

DNDi selected three targets for Atomwise’s...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >